Kurome Therapeutics is a preclinical stage company developing novel therapies that subvert cancer's ability to evade treatment. Founded on research at Cincinnati Children's Hospital Medical Center in collaboration with the National Institutes of Health's National Center for Advancing Translational Sciences (NCATS), Kurome is developing a series of combined IRAK1/4 and panFLT3 inhibitors to target cancer cells that have co-opted IRAK1/4-mediated immune signaling pathways to survive.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 06/11/21 | $15,000,000 | Series A |
Affinity Asset Advisors CincyTech Medicxi | undisclosed |
